Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. https://doi.org/10.1056/NEJMra052638
Bacigalupo A, Ballen Ok, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the depth of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004.
Santarone S, Pidala J, Di Nicola M, Subject T, Alsina M, Ayala E, et al. Fludarabine and pharmacokinetic-targeted busulfan earlier than allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transpl. 2011;17:1505–11. https://doi.org/10.1016/j.bbmt.2011.02.011.
Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G, Schönland S, et al. Diminished 8-gray in comparison with commonplace 12-gray complete physique irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a research of the acute leukemia working get together of the EBMT. Hemasphere. 2023;7:e812. https://doi.org/10.1097/hs9.0000000000000812.
Gagelmann N, Kroger N. Dose depth for conditioning in allogeneic hematopoietic cell transplantation: can we suggest “when and for whom” in 2021? Haematologica. 2021;106:1794–804. https://doi.org/10.3324/haematol.2020.268839.
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning depth in present period: a research in acute myeloid leukemia sufferers. Bone Marrow Transpl. 2020;55:1114–25. https://doi.org/10.1038/s41409-020-0803-y.
Marks R, Potthoff Ok, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Diminished-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: explicit exercise in opposition to superior hematologic malignancies. Blood. 2008;112:415–25. https://doi.org/10.1182/blood-2007-08-104745.
Hirschbuhl Ok, Labopin M, Polge E, Blaise D, Bourhis JH, Socie G, et al. Complete physique irradiation versus busulfan based mostly intermediate depth conditioning for stem cell transplantation in ALL sufferers >45 years-a registry-based research by the Acute Leukemia Working Get together of the EBMT. Bone Marrow Transpl. 2023;58:874–80. https://doi.org/10.1038/s41409-023-01966-w.
Giebel S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, Byrne JL, Fegueux N, et al. Complete physique irradiation + fludarabine in comparison with busulfan + fludarabine as “reduced-toxicity conditioning” for sufferers with acute myeloid leukemia handled with allogeneic hematopoietic cell transplantation in first full remission: a research by the Acute Leukemia Working Get together of the EBMT. Bone Marrow Transpl. 2021;56:481–91. https://doi.org/10.1038/s41409-020-01050-7.
Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146–62. https://doi.org/10.1016/S0140-6736(19)33018-1
Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, et al. Steady decreased nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution’s three decade expertise. Biol Blood Marrow Transpl. 2014;20:1217–23. https://doi.org/10.1016/j.bbmt.2014.04.021.
Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, et al. Comparability of reduced-intensity conditioning regimens in sufferers with acute lymphoblastic leukemia >45 years present process allogeneic stem cell transplantation-a retrospective research by the Acute Leukemia Working Get together of EBMT. Bone Marrow Transpl. 2020;55:1560–9. https://doi.org/10.1038/s41409-020-0878-5.
Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Selecting a reduced-intensity conditioning routine for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: a scientific evaluation and meta-analysis. Biol Blood Marrow Transpl. 2019;25:728–33. https://doi.org/10.1016/j.bbmt.2018.11.016.
Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for grownup Philadelphia-positive acute lymphoblastic leukemia. Most cancers. 2019;125:873–83. https://doi.org/10.1002/cncr.31874.
Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for grownup high-risk acute lymphoblastic leukemia in full remission. Am J Hematol. 2013;88:634–41. https://doi.org/10.1002/ajh.23465.
Lee S, Kim DW, Cho BS, Yoon JH, Shin SH, Yahng SA, et al. Influence of minimal residual illness kinetics throughout imatinib-based remedy on transplantation consequence in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26:2367–74. https://doi.org/10.1038/leu.2012.164.
Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, et al. Minimal residual disease-based impact and long-term consequence of first-line dasatinib mixed with chemotherapy for grownup Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol. 2016;27:1081–8. https://doi.org/10.1093/annonc/mdw123
Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Possible consequence of blinatumomab adopted by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Most cancers Med. 2019;8:7650–9. https://doi.org/10.1002/cam4.2680.
Yoon SY, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Expertise of blinatumomab salvage for sufferers with acute lymphoblastic leukemia presenting with remoted extramedullary relapse after earlier allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:1469–72. https://doi.org/10.1038/s41409-019-0708-9.
Lee SH, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Response to blinatumomab or inotuzumab ozogamicin for remoted extramedullary relapse of grownup acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case research. Int J Hematol. 2022;115:135–9. https://doi.org/10.1007/s12185-021-03231-6.
Yoon JH, Kwag D, Lee JH, Min GJ, Park SS, Park S, et al. Superior survival consequence of blinatumomab in contrast with typical chemotherapy for grownup sufferers with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort evaluation. Ther Adv Hematol. 2023;14:20406207231154713 https://doi.org/10.1177/20406207231154713.
Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Diminished-intensity versus typical myeloablative conditioning allogeneic stem cell transplantation for sufferers with acute lymphoblastic leukemia: a retrospective research from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–43. https://doi.org/10.1182/blood-2010-02-266551.
Kawamura Ok, Kako S, Mizuta S, Ishiyama Ok, Aoki J, Yano S, et al. Comparability of conditioning with fludarabine/busulfan and fludarabine/melphalan in allogeneic transplantation recipients 50 years or older. Biol Blood Marrow Transpl. 2017;23:2079–87. https://doi.org/10.1016/j.bbmt.2017.09.003.
Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Influence of donor kind on long-term graft-versus-host disease-free/relapse-free survival for grownup acute lymphoblastic leukemia in first remission. Bone Marrow Transpl. 2021;56:828–40. https://doi.org/10.1038/s41409-020-01097-6.
Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host illness. Nat Rev Dis Prim. 2023;9:27 https://doi.org/10.1038/s41572-023-00438-1.
Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological harm. Nat Rev Immunol. 2021;21:277–91. https://doi.org/10.1038/s41577-020-00457-z.
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning depth (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2024;59:217–23. https://doi.org/10.1038/s41409-023-02139-5.
Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparability between two fludarabine-based reduced-intensity conditioning regimens earlier than allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is related to greater incidence of acute graft-versus-host illness and non-relapse mortality and decrease incidence of relapse than fludarabine/busulfan. Leukemia. 2007;21:2109–16. https://doi.org/10.1038/sj.leu.2404886.
Quick NJ, Kantarjian H, Jabbour E. Optimizing the remedy of acute lymphoblastic leukemia in youthful and older adults: new medicine and evolving paradigms. Leukemia. 2021;35:3044–58. https://doi.org/10.1038/s41375-021-01277-3.
Teachey DT, Starvation SP. Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm. Nat Rev Clin Oncol. 2018;15:69–70. https://doi.org/10.1038/nrclinonc.2017.176.
van den Brink MR, Velardi E, Perales MA. Immune reconstitution following stem cell transplantation. Hematol Am Soc Hematol Educ Program. 2015;2015:215–9. https://doi.org/10.1182/asheducation-2015.1.215
Mensen A, Johrens Ok, Anagnostopoulos I, Demski S, Oey M, Stroux A, et al. Bone marrow T-cell infiltration throughout acute GVHD is related to delayed B-cell restoration and performance after HSCT. Blood. 2014;124:963–72. https://doi.org/10.1182/blood-2013-11-539031.
Troullioud Lucas AG, Lindemans CA, Bhoopalan SV, Dandis R, Prockop SE, Naik S, et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional evaluation. Cytotherapy. 2023;25:977–85. https://doi.org/10.1016/j.jcyt.2023.05.012.
Kuczma M, Ding ZC, Zhou G. Immunostimulatory results of melphalan and usefulness in adoptive cell remedy with antitumor CD4+ T cells. Crit Rev Immunol. 2016;36:179–91. https://doi.org/10.1615/CritRevImmunol.2016017507
Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, et al. Absolute lymphocyte rely restoration after allogeneic hematopoietic stem cell transplantation predicts scientific consequence. Biol Blood Marrow Transpl. 2015;21:873–80. https://doi.org/10.1016/j.bbmt.2015.01.019.
Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults utilizing CD3/CD19 depletion and decreased depth conditioning: a part II research. Haematologica. 2012;97:1523–31. https://doi.org/10.3324/haematol.2011.059378.
Pastore D, Delia M, Mestice A, Carluccio P, Perrone T, Gaudio F, et al. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host illness and immunologic restoration after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2012;18:887–93. https://doi.org/10.1016/j.bbmt.2011.10.039.
Divito SJ, Aasebo AT, Matos TR, Hsieh PC, Collin M, Elco CP, et al. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host illness. J Clin Make investments. 2020;130:4624–36. https://doi.org/10.1172/JCI129965
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and administration of graft versus host illness after stem-cell transplantation for haematological malignancies: up to date consensus suggestions of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157–e167. https://doi.org/10.1016/S2352-3026(19)30256-X
Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host illness prevention within the setting of allogeneic peripheral blood stem cell transplantation: a evaluation from the Acute Leukemia Working Get together of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224–34. https://doi.org/10.3324/haematol.2016.148510.
Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG/ATLG in stopping graft-versus-host illness after allogeneic stem cell transplantation: consensus-based suggestions by a global skilled panel. Bone Marrow Transpl. 2020;55:1093–102. https://doi.org/10.1038/s41409-020-0792-x.
Massoud R, Klyuchnikov E, Gagelmann N, Zabelina T, Wolschke C, Ayuk F, et al. Influence of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. Bone Marrow Transpl. 2022;57:1548–55. https://doi.org/10.1038/s41409-022-01666-x.
Heining C, Spyridonidis A, Bernhardt E, Schulte-Monting J, Behringer D, Grullich C, et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective research together with 148 sufferers. Bone Marrow Transpl. 2007;39:613–22. https://doi.org/10.1038/sj.bmt.1705648.
Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JLM. Complete physique irradiation and acute graft-versus-host illness: the position of gastrointestinal injury and inflammatory cytokines. Blood. 1997;90:3204–13. https://doi.org/10.1182/blood.V90.8.3204
Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host illness. Blood. 1992;80:2964–8. https://doi.org/10.1182/blood.V80.12.2964.2964
Johansson JE, Brune M, Ekman T. The intestine mucosa barrier is preserved throughout allogeneic, haemopoietic stem cell transplantation with decreased depth conditioning. Bone Marrow Transpl. 2001;28:737–42. https://doi.org/10.1038/sj.bmt.1703230
Kekre N, Marquez-Malaver FJ, Cabrero M, Pinana J, Esquirol A, Soiffer RJ, et al. Fludarabine/busulfan versus fludarabine/melphalan conditioning in sufferers present process reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transpl. 2016;22:1808–15. https://doi.org/10.1016/j.bbmt.2016.07.006.
Yamada Y, Ikegawa S, Najima Y, Atsuta Y, Konuma R, Adachi H, et al. Retrospective comparability of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI. Int J Hematol. 2022;115:244–54. https://doi.org/10.1007/s12185-021-03233-4.
Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:344–56. https://doi.org/10.1016/j.bbmt.2012.08.011.
Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, Barba P, Hernandez-Boluda JC, Esquirol A, et al. A time-to-event mannequin for acute kidney harm after reduced-intensity conditioning stem cell transplantation utilizing a tacrolimus- and sirolimus-based graft-versus-host illness prophylaxis. Biol Blood Marrow Transpl. 2017;23:1177–85. https://doi.org/10.1016/j.bbmt.2017.03.035.
Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE et al. Scientific options of acute kidney harm within the early post-transplantation interval following reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2023. https://doi.org/10.1016/j.jtct.2023.03.029
Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2009;15:523–36. https://doi.org/10.1016/j.bbmt.2008.12.489.
Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as a part of a busulfan/cyclophosphamide preparative routine for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive illness (HVOD), HVOD-related mortality, and general 100-day mortality. Biol Blood Marrow Transpl. 2002;8:493–500. https://doi.org/10.1053/bbmt.2002.v8.pm12374454
Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in kids: a scientific and pharmacological research. Most cancers Res. 1990;50:6203–7.
Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, et al. The affect of particular person comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 2018;32:1787–94. https://doi.org/10.1038/s41375-018-0185-y.
Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, et al. Influence of conditioning with TBI in grownup sufferers with T-cell ALL who obtain a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working get together of EBMT. Bone Marrow Transpl. 2016;51:351–7. https://doi.org/10.1038/bmt.2015.278.
Chen GL, Hahn T, Wilding GE, Groman A, Hutson A, Zhang Y, et al. Diminished-intensity conditioning with fludarabine, melphalan, and complete physique irradiation for allogeneic hematopoietic cell transplantation: the impact of accelerating melphalan dose on underlying illness and toxicity. Biol Blood Marrow Transpl. 2019;25:689–98. https://doi.org/10.1016/j.bbmt.2018.09.042.
